Skip to main content

Research Repository

Advanced Search

Outputs (5)

Tremelimumab for the treatment of malignant mesothelioma (2015)
Journal Article
Guazzelli, A., Hussain, M., Krstic- Demonacos, M., & Mutti, L. (2015). Tremelimumab for the treatment of malignant mesothelioma. Expert Opinion on Biological Therapy, 15(12), 1819-1829. https://doi.org/10.1517/14712598.2015.1116515

Introduction: Tremelimumab demonstrated therapeutic activity in different malignancies, including malignant pleural mesothelioma (MPM); however, continued research could improve the therapeutic index of this agent. Areas covered: This review descr... Read More about Tremelimumab for the treatment of malignant mesothelioma.

Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo (2015)
Journal Article
Miluzio, A., Oliveto, S., Pesce, E., Mutti, L., Murer, B., Grosso, S., …Biffo, S. (2015). Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo. Oncotarget, 2015(6), 37471-37485. https://doi.org/10.18632/oncotarget.5462

eIF6 is an antiassociation factor that regulates the availability of active 80S. Its activation is driven by the RACK1/PKCβ axis, in a mTORc1 independent manner. We previously described that eIF6 haploinsufficiency causes a striking survival in the E... Read More about Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo.

The expanded p53 interactome as a predictive model for cancer therapy (2015)
Journal Article
Hussain, M., Tian, K., Mutti, L., Krstic-Demonacos, M., & Schwartz, J. (2015). The expanded p53 interactome as a predictive model for cancer therapy. Genomics and computational biology, 1(1), e20. https://doi.org/10.18547/gcb.2015.vol1.iss1.e20

The tumour suppressor gene TP53 is implicated in the majority of all human cancers, thus pivotal to genomic integrity. Even though over 72,000 PubMed publications are linked with the keyword p53 and this number is continuously increasing, due to... Read More about The expanded p53 interactome as a predictive model for cancer therapy.

The role of microenvironment and immunity in drug response in leukemia (2015)
Journal Article
Bakker, E., Qattan, M., Mutti, L., Demonacos, C., & Krstic- Demonacos, M. (2015). The role of microenvironment and immunity in drug response in leukemia. BBA - Molecular Cell Research, 1863(3), 414-426. https://doi.org/10.1016/j.bbamcr.2015.08.003

Leukemia is a cancer of the white blood cells, with over 54,000 new cases per year diagnosed worldwide and a 5-year survival rate below 60%. This highlights a need for research into the mechanisms behind its etiology and causes of therapy failure. Th... Read More about The role of microenvironment and immunity in drug response in leukemia.